Copyright
©The Author(s) 2021.
World J Gastrointest Surg. May 27, 2021; 13(5): 392-405
Published online May 27, 2021. doi: 10.4240/wjgs.v13.i5.392
Published online May 27, 2021. doi: 10.4240/wjgs.v13.i5.392
Table 2 Clinical trials in transplantation vs best medical therapy for liver-limited colorectal metastases
| Ref. | Study | n | Characteristics | Intervention | Overall survival | Progression free survival |
| Hagness et al[75] | SECA-I | 21 | Unresectable; > 6 mo of neoadjuvant therapy | Liver transplant | 5-yr OS: 60% | 5-yr RFS: 33% |
| Dueland et al[68] | SECA-II | 15 | Unresectable; at least a 10% response to systemic therapy; disease stability 12 mo | Liver transplant | 5-yr OS: 83% | 3-yr RFS: 35% |
| Tveit et al[76] | NORDIC VII | 566 | Metastatic CRC; treatment-naïve; no resection with curative intent | A: FLOX alone; B: FLOX + Cetuximab; C: Cetuximab + Intermittent FLOX | 3-yr OS: 6-8% | 1-yr PFS: 20-32% |
- Citation: Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021; 13(5): 392-405
- URL: https://www.wjgnet.com/1948-9366/full/v13/i5/392.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v13.i5.392